Study Phase 4

A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient's Self-reported Symptoms and Their Impacts

Trial Information

Generic NameSelexipagProduct NameUPTRAVI®Therapeutic AreaBlood and Blood-Forming OrgansProduct ClassAntithrombotic AgentsPharmacological SubgroupAntithrombotic AgentsChemical SubgroupPlatelet Aggregation Inhibitors, excluding HeparinCondition StudiedPulmonary Arterial Hypertension
Sponsor Protocol NumberAC-065A404Enrollment108Data PartnerJohnson & Johnson% Female71.3%Mean/Median Age (Years)49.4% White88.9%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.